Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Overview

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Companies Involved in Therapeutics Development

Ahn-Gook Pharmaceutical Co Ltd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Daewoong Pharmaceutical Co Ltd

Eisai Co Ltd

Handa Pharmaceuticals LLC

Ilyang Pharmaceutical Co Ltd

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

RaQualia Pharma Inc

Sam-A Pharm Co Ltd

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

Yooyoung Pharm Co Ltd

Yuyu Pharma Inc

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Drug Profiles

(esomeprazole + sodium bicarbonate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

azeloprazole sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceclazepide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-20043 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-30065 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

colesevelam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexlansoprazole DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-14012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

esomeprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-17DT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HND-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilaprazole DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IYHCR-17 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-1366 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naronapride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netazepide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pantoprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pantoprazole DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00000774 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SA-15001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vonoprazan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YY-DXR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Product Development Milestones

Featured News & Press Releases

Oct 08, 2018: Ironwood Pharmaceuticals presents IW-3718 data at the American College of Gastroenterology 2018 Annual Scientific Meeting

Jul 06, 2018: Ministry approves CJ Healthcares Gastro esophageal reflux treatment

Jul 06, 2018: RaQualia Announces Receipt of Milestone Payment from CJ HealthCare

Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718

Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018

Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018

May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastro esophageal Reflux Disease (GERD) at Digestive Disease Week 2018

Apr 16, 2018: First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD

Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastro esophageal Reflux Disease

Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017

Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride

Jul 11, 2016: Takeda Announces FDA Approval of Dexilant (dexlansoprazole) for Patients 12-17 Years of Age

Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastro esophageal Reflux Disease

Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea

Jan 27, 2016: FDA Approves Takeda’s Dexilant SoluTab (dexlansoprazole)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H1 2019, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastro esophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastro esophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 6, 6, 4, 1 and 1 respectively.

Reflux Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Reflux Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.